Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CTMX 
CytomX Therapeutics Inc (CTMX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: CTMX (5-star) is a STRONG-BUY. BUY since 21 days. Simulated Profits (12.41%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6.14
1 Year Target Price $6.14
| 2 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 55.12% | Avg. Invested days 31 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 537.62M USD | Price to earnings Ratio 6.52 | 1Y Target Price 6.14 |
Price to earnings Ratio 6.52 | 1Y Target Price 6.14 | ||
Volume (30-day avg) 6 | Beta 2.27 | 52 Weeks Range 0.40 - 3.91 | Updated Date 10/25/2025 |
52 Weeks Range 0.40 - 3.91 | Updated Date 10/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 34.01% | Operating Margin (TTM) -6.89% |
Management Effectiveness
Return on Assets (TTM) 16.13% | Return on Equity (TTM) 108.21% |
Valuation
Trailing PE 6.52 | Forward PE 14.2 | Enterprise Value 389712331 | Price to Sales(TTM) 3.81 |
Enterprise Value 389712331 | Price to Sales(TTM) 3.81 | ||
Enterprise Value to Revenue 2.76 | Enterprise Value to EBITDA 8.72 | Shares Outstanding 164912906 | Shares Floating 120279228 |
Shares Outstanding 164912906 | Shares Floating 120279228 | ||
Percent Insiders 0.79 | Percent Institutions 90.2 |
Upturn AI SWOT
CytomX Therapeutics Inc
Company Overview
History and Background
CytomX Therapeutics Inc. was founded in 2008. It's a biopharmaceutical company focused on developing conditionally activated antibody therapeutics for cancer. The company's Probody platform is designed to enable safer and more effective cancer treatments.
Core Business Areas
- Therapeutics Development: Focuses on discovering, developing, and commercializing novel antibody-based therapies for the treatment of cancer.
- Probody Platform Technology: This proprietary platform is central to their therapeutic development efforts, allowing for the creation of conditionally activated antibodies.
- Partnerships and Licensing: Collaborates with other pharmaceutical companies to develop and commercialize Probody therapeutics.
Leadership and Structure
Sean McCarthy is the CEO. The company has a typical biotech organizational structure with research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- CX-2009 (Probody Drug Conjugate targeting CD166): An investigational Probody Drug Conjugate (PDC) designed to target CD166, a protein highly expressed in various cancers. Currently in clinical trials. Competitors include companies developing ADCs targeting similar tumor antigens.
- CX-904 (Conditionally activated anti-CTLA-4 antibody): A conditionally activated anti-CTLA-4 antibody being developed in collaboration with Amgen. In clinical trials. Competitors include companies developing CTLA-4 inhibitors like Bristol Myers Squibb (ipilimumab).
Market Dynamics
Industry Overview
The oncology market is large and rapidly growing, with significant unmet needs. Targeted therapies, including antibody-based drugs, are a major focus.
Positioning
CytomX is positioned as an innovator in the field of conditionally activated antibody therapeutics. Their Probody platform aims to address the toxicity challenges associated with traditional antibody therapies.
Total Addressable Market (TAM)
The total oncology market is projected to be hundreds of billions of dollars. CytomX's positioning allows it to capture a share of the targeted therapy market, estimated to be a significant portion of the overall market.
Upturn SWOT Analysis
Strengths
- Proprietary Probody platform technology
- Strong partnerships with major pharmaceutical companies
- Focus on innovative cancer therapies
- Experienced management team
Weaknesses
- Reliance on early-stage clinical trials
- High cash burn rate
- Potential for clinical trial failures
- Dependence on partnerships for revenue
Opportunities
- Expansion of Probody platform to new targets
- Advancement of clinical programs
- Strategic acquisitions or partnerships
- Increasing demand for targeted cancer therapies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Economic downturn
Competitors and Market Share
Key Competitors
- BMY
- MRK
- LLY
- AZN
Competitive Landscape
CytomX faces competition from larger pharmaceutical companies with more established oncology franchises. Its competitive advantage lies in its Probody platform and innovative approach to targeted therapy, but it needs to demonstrate clinical success.
Growth Trajectory and Initiatives
Historical Growth: Growth has been tied to the advancement of its clinical programs and partnerships.
Future Projections: Future growth depends on clinical trial success, regulatory approvals, and commercialization of its products. Analyst estimates vary.
Recent Initiatives: Focus on advancing clinical programs, expanding partnerships, and exploring new applications of the Probody platform.
Summary
CytomX Therapeutics is an early-stage biotech company with a promising Probody platform for developing conditionally activated antibody therapies. Its strength lies in its innovative technology and partnerships, but it faces challenges related to clinical development risks and competition from larger companies. The future of CytomX hinges on the success of its clinical trials and its ability to secure additional partnerships. Maintaining a strong cash position is essential for navigating the expensive and time-consuming drug development process.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Financial data and market information are subject to change. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CytomX Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2015-10-08 | Chairman & CEO Dr. Sean A. McCarthy DPHIL | ||
Sector Healthcare | Industry Biotechnology | Full time employees 119 | Website https://www.cytomx.com |
Full time employees 119 | Website https://www.cytomx.com | ||
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.